POLE and neoplasm: This has already been reported in diverse studies [58,59,60] and suggest that TILs, PD-L1 [61], and tumor mutational burden (TMB) [62] could be excellent alternatives as biomarkers, especially in the POLE-ultramutated subtype, since determining the POLE mutational status may require more complex and expensive molecular techniques.